What's new? Log in Free sign up

Dyne Therapeutics (DYN)

Company Profile

Company profile

Ticker

DYN

Exchange

Website

www.dyne-tx.com

CEO

Mr. John G. Cox M.B.A.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Madison Square Garden Entertainment Corp., MSG ENTERTAINMENT SPINCO, INC.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Dyne Therapeutics Securities Corporation ...

IRS number

364883909

DYN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$43.50

Low target

$17.00

High target

$50.00

Chardan Capital

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

15 Apr 25

Registration of securities for employees

Departure of Directors or Certain Officers

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Registration of securities for employees

Results of Operations and Financial Condition

Latest ownership filings

View all

BlackRock, Inc.

Johanna Friedl-Naderer

Richard William Scalzo

Oxana Beskrovnaya

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart DYN financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	437.39 mm	437.39 mm	437.39 mm	437.39 mm	437.39 mm	437.39 mm
Cash burn (monthly)	32.24 mm	(no burn)	32.37 mm	28.66 mm	28.11 mm	24.36 mm
Cash used (since last report)	126.74 mm	n/a	127.26 mm	112.66 mm	110.52 mm	95.79 mm
Cash remaining	310.66 mm	n/a	310.13 mm	324.73 mm	326.87 mm	341.60 mm
Runway (months of cash)	9.6	n/a	9.6	11.3	11.6	14.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

DYN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	203	205	-1.0%
Opened positions	37	45	-17.8%
Closed positions	39	36	+8.3%
Increased positions	67	73	-8.2%
Reduced positions	62	55	+12.7%

13F shares	Current	Prev Q	Change
Total value	2.56 tn	3.91 tn	-34.4%
Total shares	128.76 mm	129.18 mm	-0.3%
Total puts	434.50 k	238.10 k	+82.5%
Total calls	135.10 k	234.00 k	-42.3%
Total put/call ratio	3.2	1.0	+216.1%

Largest owners	Shares	Value	Change
Atlas Venture Life Science Advisors	8.02 mm	$188.94 bn	-0.0%
FMR	8.00 mm	$188.41 bn	-11.4%
BlackRock	7.95 mm	$187.29 bn	+2.0%
JHG Janus Henderson	7.38 mm	$173.81 bn	+8.3%
Vanguard	6.70 mm	$157.94 bn	-2.3%
Ra Capital Management	6.38 mm	$150.34 bn	0.0%
Capital Fund IV Cooperatief U.A. Forbion	5.80 mm	$169.23 mm	0.0%
Atlas Venture Fund XI	5.71 mm	$166.85 mm	0.0%
FCPM Iii Services B.V.	5.46 mm	$128.70 bn	-8.3%
RTW Investments	5.22 mm	$122.95 bn	-23.5%

Largest transactions	Shares	Bought/sold	Change
JEF Jefferies Financial	1.80 mm	+1.80 mm	NEW
RTW Investments	5.22 mm	-1.60 mm	-23.5%
Deep Track Capital	2.00 mm	-1.28 mm	-39.1%
FMR	8.00 mm	-1.03 mm	-11.4%
Norges Bank	950.10 k	+950.10 k	NEW
First Light Asset Management	420.43 k	-836.85 k	-66.6%
Point72 Asset Management	924.68 k	+822.20 k	+802.3%
Braidwell	681.18 k	+681.18 k	NEW
Avoro Capital Advisors	0.00	-650.00 k	EXIT
JHG Janus Henderson	7.38 mm	+566.15 k	+8.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

DYN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Mar 25	Erick Lucera	Common Stock	Grant	Acquire A	No	No	0	66,100	0.00	66,100
31 Mar 25	Erick Lucera	Stock Option Common Stock	Grant	Acquire A	No	No	10.46	214,500	2.24 mm	214,500
13 Mar 25	Johanna Friedl-Naderer	Common Stock	Sell	Dispose S	No	Yes	12.12	143	1.73 k	96,057
11 Mar 25	Richard William Scalzo	Common Stock	Sell	Dispose S	No	Yes	11.38	1,343	15.28 k	122,330
11 Mar 25	Oxana Beskrovnaya	Common Stock	Sell	Dispose S	No	Yes	11.38	2,153	24.50 k	195,840

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

EC Grants Orphan Drug Designation For Dyne Therapeutics' DYNE-251 For Treatment Of Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months -- Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 -WALTHAM,

Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session

JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path

JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.

JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $17

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $46 Price Target

Press releases

From Benzinga Pro

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 -

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, Mass., April 15,

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.